Primary Analysis of a Phase 1/2 Study to Assess MultiStem® Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST-ARDS)

Jonathan Bannard-Smith

doi:10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7353

Primary Analysis of a Phase 1/2 Study to Assess MultiStem® Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST-ARDS)

Division of Immunology, Immunity to Infection and Respiratory Medicine

Research output: Contribution to conference › Abstract

Original language	Undefined
DOIs	https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7353
Publication status	Published - May 2019

Access to Document

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7353

Cite this

@conference{61535a4c58d741988e6739a9fc84cf66,

title = "Primary Analysis of a Phase 1/2 Study to Assess MultiStem{\textregistered} Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST-ARDS)",

author = "Jonathan Bannard-Smith",

year = "2019",

month = may,

doi = "10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7353",

language = "Undefined",

}

TY - CONF

T1 - Primary Analysis of a Phase 1/2 Study to Assess MultiStem® Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST-ARDS)

AU - Bannard-Smith, Jonathan

PY - 2019/5

Y1 - 2019/5

UR - http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7353

U2 - 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7353

DO - 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7353

M3 - Abstract

ER -

Primary Analysis of a Phase 1/2 Study to Assess MultiStem® Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST-ARDS)

Access to Document

Other files and links

Cite this